Back to list

anaSTILLs

University of North Carolina at Chapel Hill


Description

The aim of this study is to demonstrate the efficacy of anakinra in Still's disease.


Keywords:

Arthritis, Auto Immune Diseases, Joints, Pain, Pediatrics


Category:

Drug or Biologic
Phase:3

Qualifications

 


Age
0 - 0 years


Gender
Any


Study Population

Newly diagnosed Still's disease, including SJIA (Systemic juvenile idiopathic arthritis) and AOSD (Adult-onset Still's disease).


Investigator

Eveline Wu
Clinical Assistant Professor
Pediatrics - Allergy Immunology and Rheumatology

For questions, contact:

Julie Walker, CCRC
julie_walker@med.unc.edu
(919) 843-6619


Recruitment Period End

December 30, 2019

Location

Primary Location
Clinical & Translational Research Center
Burnett-Womack Building, 160 Dental Cir, Chapel Hill, NC 27514, USA

Study Qualifications

Gender Any

Age Range 0 - 0 years

Participant qualification(s) Weight >/= 10kg If taking methotrexate must be on stable dose for 8 weeks Active Arthritis >/= 1 joint CRP > 30mg/L At least one fever (> 100.4) related to disease within 1 week prior to randomization

Not eligible if: Diagnosed with Still's Disease greater than 6months prior to randomization Participation in another clinical interventional study w/in 30 days Previous treatment with anakinra

Number of Visits

    » 7 In person visit(s)

    1 screening, 5 clinic visits

    » 2 Remote visit(s)

    2 phone calls

Participation Period

16 weeks

Compensation

By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.